Kristina Dunder

Dag Hammarskjolds Vag 42, Uppsala Science Park
Uppsala, C 75237, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis.

The European Medicines Agency evaluation of nemolizumab (Nemluvio) for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis.

Journal: The British journal of dermatology

Published: June 25, 2025

New guideline of the European Medicines Agency (EMA) on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus.

New guideline of the European Medicines Agency (EMA) on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus.

Journal: Diabetologia

Published: March 27, 2024

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.

The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.

Journal: ESMO open

Published: October 09, 2020

The European Medicines Agency's approval of new medicines for type 2 diabetes.

The European Medicines Agency's approval of new medicines for type 2 diabetes.

Journal: Diabetes, obesity & metabolism

Published: November 21, 2017

Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Comment on the editorial by Turner et al. on assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion by Zannad et al.

Journal: European heart journal. Cardiovascular pharmacotherapy

Published: April 27, 2017

Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.

Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.

Journal: Archives of disease in childhood

Published: October 27, 2016

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Journal: The New England journal of medicine

Published: February 28, 2014

The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.

The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.

Journal: The oncologist

Published: April 26, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026